Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 47 out of 100. Down syndrome and Alzheimer's

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

Novel insights into Alzheimer's disease through the study of individuals with Down syndromePeople with Down syndrome (DS) represent the largest genetically defined population at risk for Alzheimer's disease (AD). 1 Virtually all adults with DS develop AD neuropathology by midlife due to triplication of the amyloid precursor protein (APP) gene on chromosome 21.As medical advances and social integration have extended life expectancy into the 60s, AD has emerged as the major determinant of cognitive decline, morbidity, and mortality in this DS population. 2 What was once viewed as an inevitable consequence of aging in DS is now recognized as a unique scientific opportunity to uncover the earliest events that drive AD.The predictable and accelerated course of DS-associated AD (DSAD) provides an unparalleled window into the molecular and cellular origins of amyloid and tau pathology, neuroinflammation, cerebrovascular pathology, and neurodegeneration.It allows us to study, with precision, the sequence of pathological changes long before symptoms emerge.This is knowledge that benefits not only individuals with DS but also the broader AD community seeking to prevent disease before it begins.The past decade has witnessed a transformation in DSAD research, driven by unprecedented collaboration, infrastructure, and investment.Large-scale international initiatives such as the Alzheimer's Biomarker Consortium-Down Syndrome (ABC-DS), 3,4 the Down Alzheimer Barcelona Neuroimaging Initiative (DABNI), 5 the Horizon 21 Consortium (https://horizon-21.org/) 6 and the Trial Ready Cohort-Down Syndrome (TRC-DS) (https://www.trcds.org/)are reshaping our understanding of the natural history of AD in DS.Together, these cohorts provide longitudinal, multimodal data encompassing clinical, cognitive, fluid, imaging, and genetic measures, allowing harmonized comparisons across continents and with sporadic and autosomal dominant forms of AD.Equally important has been the extraordinary increase in research investment, particularly through the National Institutes of Health (NIH) and its National Institute on Aging (NIA), catalyzed by the INCLUDE (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE) Project (https://www.nih.gov/ include-project).This strategic funding initiative has enabled infrastructure for multi-site studies, data sharing, and advanced biomarker development, while also fostering the training and expansion of a new generation of DSAD

What this study adds

Evidence grade: Moderate

This is a follow-up (cohort) study. This review explains that studying people with Down syndrome, who almost all develop Alzheimer's pathology by midlife, offers a unique chance to understand the earliest steps of the disease. This knowledge could help prevent Alzheimer's not only in Down syndrome but also in the broader population.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Head, E., Cohen, A. D., Fortea, J., & McGlinchey, E. (2026). Novel insights into Alzheimer's disease through the study of individuals with Down syndrome. Alzheimer s & Dementia. https://doi.org/10.1002/alz.71074

Vancouver

Head E, Cohen AD, Fortea J, McGlinchey E. Novel insights into Alzheimer's disease through the study of individuals with Down syndrome. Alzheimer s & Dementia. 2026. doi:10.1002/alz.71074. PMID: 41505228.

BibTeX

@article{head2026-41505228,
  author  = {Head, Elizabeth and Cohen, Ann D. and Fortea, Juan and McGlinchey, Eimear},
  title   = {{Novel insights into Alzheimer's disease through the study of individuals with Down syndrome}},
  journal = {Alzheimer s \& Dementia},
  year    = {2026},
  doi     = {10.1002/alz.71074},
  pmid    = {41505228},
  url     = {https://doi.org/10.1002/alz.71074}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.

Key findings

Why it matters

This review explains that studying people with Down syndrome, who almost all develop Alzheimer's pathology by midlife, offers a unique chance to understand the earliest steps of the disease. This knowledge could help prevent Alzheimer's not only in Down syndrome but also in the broader population.

Study details

How this study scored 47/100
How this study's score is builtJournal tier 7 of 10; Journal's citation record 2 of 4; Study design 7 of 12; Strength of evidence 3 of 5; Peer-review validation 10 of 10; How recent 5 of 5; Sample size 0 of 4; Effect reported 0 of 3; Studied in people 0 of 3; Randomized / blinded 0 of 2; Times cited 1 of 7; Citations per year 0 of 5; Impact for its field and year 3 of 6; Cited by studies here 1 of 6; Still being cited 0 of 4; Senior author's track record 1 of 4; Institution's track record 1 of 3; Multicenter collaboration 2 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 47 of 100.47 of 100 points earned53 not earned

Published in a peer-reviewed journal, and it is a longitudinal study following the same people over time. Scored zero for sample size, effect reported, studied in people and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 7 / 10 Tier 3 — peer-reviewed journal (Alzheimer s & Dementia)
Journal's citation record 2 / 4 Alzheimer s & Dementia: journal h-index 228 (OpenAlex, 2026-10-29)
Study design 7 / 12 A longitudinal study following the same people over time
Strength of evidence 3 / 5 Rated “moderate” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 5 / 5 2026 — within 1 year(s) of the newest study here
Sample size 0 / 4 Participant count not stated — scores zero (not stated in the record — scored 0)
Effect reported 0 / 3 No effect size reported — scores zero (not stated in the record — scored 0)
Studied in people 0 / 3 Not stated whether this was studied in people — scores zero (not stated in the record — scored 0)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 1 / 7 Cited 1 times (OpenAlex, 2026-10-10)
Citations per year 0 / 5 0.5 citations a year over 2 year(s) since 2026
Impact for its field and year 3 / 6 Cited 6.4× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 1 / 6 Cited by 1 other studies in this library
Still being cited 0 / 4 Cited 1 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 1 / 4 Last-listed author Eimear McGlinchey: h-index 15 (OpenAlex, whole career)
Institution's track record 1 / 3 University of Pittsburgh: institution h-index 1,470 (OpenAlex)
Multicenter collaboration 2 / 3 OpenAlex lists 5 institution(s) in 3 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 41505228)
Free to read 2 / 2 Free to read
Total 47 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here.

Later studies that cite this one

1 study in the alzhub library lists this one in its references.

Related studies in Down syndrome and Alzheimer's from nearby years

Also tagged “down”

527 studies in the library carry the topic tag “down”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 527 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Down syndrome and Alzheimer's

See all studies in Down syndrome and Alzheimer's →